Core Insights - The Chinese health consumption market is undergoing a significant structural transformation, with consumers shifting from a traditional "seek medical help only when sick" approach to proactive health management throughout their life cycle [1] - This shift is driven by increased public health risk awareness, enhanced consumer health cognition, and factors such as digital technology proliferation, policy guidance, and demographic changes [1] - Companies in the health consumption sector must quickly identify and address the pain points faced by Chinese consumers in proactive health management, which requires keen insight and systematic innovation [1] Industry Trends - Bayer's Health Consumer Division is breaking away from the conventional "global formula introduction" and "mature model replication" strategies, focusing instead on localized solutions that meet the unique demands of Chinese consumers [2] - In 2025, Bayer launched innovative health solutions tailored to local needs, enhancing its product portfolio and contributing to the high-quality development of the Chinese health consumption market [2] Health Issues Addressed - Allergic rhinitis is a growing public health issue in China, with self-reported cases increasing by nearly 100 million from 2005 to 2011 [5] - The prevalence of allergic rhinitis among children rose from 14.81% (2001-2011) to 19.75% (2012-2021), indicating a concerning trend [5] - Bayer is focusing on allergic conditions, launching new products like the mometasone nasal spray in 2025 to better meet the needs of patients [5] Product Innovations - Bayer introduced the Daxin® lactulose oral solution in collaboration with JD Health to address chronic constipation, which affects approximately 140 million adults in China [6][7] - The company also launched the upgraded Bepanthen B5 cream for babies, designed to protect sensitive skin, showcasing a shift from global formulas to products specifically developed for Chinese consumers [7] Collaborative Innovation - Bayer is establishing a "co-creation platform" to foster open innovation, moving away from traditional closed R&D models [10] - The Bayer China Innovation Cooperation Center, launched in October 2024, aims to integrate local research with global resources to accelerate the transformation of scientific advancements into consumer health solutions [10][12] Market Strategy - Bayer's strategy has evolved from merely importing foreign products to co-creating solutions based on Chinese consumer needs, as seen in products like One A Day fish oil and Alevin children's calcium [13] - The company emphasizes a proactive approach to health management, focusing on prevention and scientific intervention rather than just treatment [14] Global Impact - Bayer's innovations in China are not only enhancing local health management but are also being recognized globally, with successful products entering the Asia-Pacific market and beyond [17][18] - The company's commitment to leveraging local insights for global competitiveness highlights China's role as a source of innovation in the health consumption sector [18][19]

Core Insights - Bayer's Health Consumer Division showcased five "global first" innovative products at the 8th China International Import Expo, emphasizing its commitment to providing comprehensive health solutions throughout consumers' life cycles [1][6][11] - The company views the expo as a vital platform for connecting the Chinese market with global resources, reflecting confidence in China's supply chain and innovation potential [4][23] Product Innovations - Bayer's new products address specific health management needs, including a B5 cream for diaper rash, a nasal spray for allergic rhinitis, a lactulose solution for constipation, high-purity EPA fish oil for cardiovascular health, and a calcium supplement for children [9][10][19] - The B5 cream is designed for sensitive skin, providing 16 hours of protection, while the nasal spray is recommended for children and adults [9][10] Strategic Collaborations - Bayer is deepening local collaborations through its China Innovation Cooperation Center (CCIP), focusing on "产学研" (industry-academia-research) partnerships to enhance health accessibility [13][17] - Strategic agreements were signed with local partners, including Shanghai Tianwu Technology for AI applications in health management and Shandong Jingwei Pharmaceutical for self-care solutions [15][17] Health Education Initiatives - Bayer hosted various health education activities at the expo, including forums on AI in health management and lectures on allergy prevention and digestive health [19][21] - The company aims to enhance public understanding of health issues through these initiatives, addressing consumer pain points in allergy treatment and digestive health [21][23] Global Innovation Strategy - Bayer positions the expo as a strategic anchor for its operations in China, linking local insights with global research and development [23] - The company is expanding its product offerings from local markets to international ones, exemplified by its collaboration with Xianle Health to reach broader markets [23]